Compare Fulford India with Biocon Ltd - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

FULFORD INDIA vs BIOCON - Comparison Results

FULFORD INDIA     Change

Fulford (India) Limited is an Indian affiliate of Schering-Plough Corporation, USA. The company has presence in oncology, virology and cardiovascular segments. In FY06 the topline of the company grew by 15.5% to Rs. 1519 m from Rs. 1279 m in FY05. PA... More

BIOCON  
   Change

Biocon is India's largest biotechnology company with presence in biopharmaceuticals, custom research and clinical research. It started as an enzymes manufacturer and later evolved into an integrated biopharmaceutical company. The company has two subs... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    FULFORD INDIA BIOCON FULFORD INDIA/
BIOCON
 
P/E (TTM) x 398.8 25.6 1,559.4% View Chart
P/BV x 6.2 3.4 183.5% View Chart
Dividend Yield % 0.1 0.3 24.8%  

Financials

 FULFORD INDIA   BIOCON
EQUITY SHARE DATA
    FULFORD INDIA
Mar-14
BIOCON
Mar-18
FULFORD INDIA/
BIOCON
5-Yr Chart
Click to enlarge
High Rs9421,188 79.3%   
Low Rs450305 147.5%   
Sales per share (Unadj.) Rs691.468.7 1,006.0%  
Earnings per share (Unadj.) Rs11.57.6 151.8%  
Cash flow per share (Unadj.) Rs15.414.0 109.9%  
Dividends per share (Unadj.) Rs2.001.00 200.0%  
Dividend yield (eoy) %0.30.1 214.5%  
Book value per share (Unadj.) Rs380.086.3 440.1%  
Shares outstanding (eoy) m3.90600.00 0.7%   
Bonus/Rights/Conversions -IS-  
Price / Sales ratio x1.010.9 9.3%   
Avg P/E ratio x60.798.9 61.4%  
P/CF ratio (eoy) x45.353.4 84.8%  
Price / Book Value ratio x1.88.6 21.2%  
Dividend payout %17.413.2 131.8%   
Avg Mkt Cap Rs m2,714447,900 0.6%   
No. of employees `0000.46.1 7.2%   
Total wages/salary Rs m5059,311 5.4%   
Avg. sales/employee Rs Th6,073.06,705.8 90.6%   
Avg. wages/employee Rs Th1,137.41,514.2 75.1%   
Avg. net profit/employee Rs Th100.7736.9 13.7%   
INCOME DATA
Net Sales Rs m2,69641,234 6.5%  
Other income Rs m1252,062 6.1%   
Total revenues Rs m2,82243,296 6.5%   
Gross profit Rs m-468,291 -0.6%  
Depreciation Rs m153,851 0.4%   
Interest Rs m10615 1.5%   
Profit before tax Rs m545,887 0.9%   
Minority Interest Rs m0213 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m101,569 0.6%   
Profit after tax Rs m454,531 1.0%  
Gross profit margin %-1.720.1 -8.6%  
Effective tax rate %17.726.7 66.3%   
Net profit margin %1.711.0 15.1%  
BALANCE SHEET DATA
Current assets Rs m1,73841,486 4.2%   
Current liabilities Rs m54521,413 2.5%   
Net working cap to sales %44.348.7 90.9%  
Current ratio x3.21.9 164.7%  
Inventory Days Days4864 75.8%  
Debtors Days Days494 4.6%  
Net fixed assets Rs m1250,661 0.0%   
Share capital Rs m393,000 1.3%   
"Free" reserves Rs m1,44348,808 3.0%   
Net worth Rs m1,48251,808 2.9%   
Long term debt Rs m017,898 0.0%   
Total assets Rs m2,07799,897 2.1%  
Interest coverage x6.710.6 63.5%   
Debt to equity ratio x00.3 0.0%  
Sales to assets ratio x1.30.4 314.6%   
Return on assets %2.65.2 50.7%  
Return on equity %3.08.7 34.5%  
Return on capital %4.39.6 44.7%  
Exports to sales %00-   
Imports to sales %24.50-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs m659NA-   
Fx inflow Rs m1712,058 0.1%   
Fx outflow Rs m6737,348 9.2%   
Net fx Rs m-6564,710 -13.9%   
CASH FLOW
From Operations Rs m906,621 1.4%  
From Investments Rs m105-6,840 -1.5%  
From Financial Activity Rs m-14-2,397 0.6%  
Net Cashflow Rs m181-2,612 -6.9%  

Share Holding

Indian Promoters % 0.0 40.4 -  
Foreign collaborators % 75.0 20.6 364.1%  
Indian inst/Mut Fund % 3.8 8.4 45.2%  
FIIs % 0.1 10.7 0.9%  
ADR/GDR % 0.0 0.0 -  
Free float % 21.2 19.9 106.5%  
Shareholders   4,783 109,995 4.3%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare FULFORD INDIA With:   NATCO PHARMA  PANACEA BIOTECH  GLENMARK PHARMA  ABBOTT INDIA  FRESENIUS KABI ONCO.  

Compare FULFORD INDIA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Retail Inflation Data, Air Passenger Traffic in November, and Top Cues in Focus Today(Pre-Open)

On Friday, Indian share markets witnessed positive trading activity throughout the day and ended on a strong note.

Related Views on News

BIOCON Announces Quarterly Results (2QFY20); Net Profit Down 30.5% (Quarterly Result Update)

Nov 1, 2019 | Updated on Nov 1, 2019

For the quarter ended September 2019, BIOCON has posted a net profit of Rs 3 bn (down 30.5% YoY). Sales on the other hand came in at Rs 16 bn (up 19.0% YoY). Read on for a complete analysis of BIOCON 's quarterly results.

BIOCON Announces Quarterly Results (1QFY20); Net Profit Down 11.5% (Quarterly Result Update)

Jul 29, 2019 | Updated on Jul 29, 2019

For the quarter ended June 2019, BIOCON has posted a net profit of Rs 1 bn (down 11.5% YoY). Sales on the other hand came in at Rs 5 bn (down 57.2% YoY). Read on for a complete analysis of BIOCON 's quarterly results.

BIOCON Announces Quarterly Results (4QFY19); Net Profit Down 53.8% (Quarterly Result Update)

Apr 26, 2019 | Updated on Apr 26, 2019

For the quarter ended March 2019, BIOCON has posted a net profit of Rs 705 m (down 53.8% YoY). Sales on the other hand came in at Rs 8 bn (down 34.7% YoY). Read on for a complete analysis of BIOCON 's quarterly results.

BIOCON LTD Announces Quarterly Results (3QFY19); Net Profit Up 169.2% (Quarterly Result Update)

Jan 28, 2019 | Updated on Jan 28, 2019

For the quarter ended December 2018, BIOCON LTD has posted a net profit of Rs 2 bn (up 169.2% YoY). Sales on the other hand came in at Rs 15 bn (up 45.6% YoY). Read on for a complete analysis of BIOCON LTD's quarterly results.

BIOCON LTD Announces Quarterly Results (2QFY19); Net Profit Up 501.9% (Quarterly Result Update)

Nov 9, 2018 | Updated on Nov 9, 2018

For the quarter ended September 2018, BIOCON LTD has posted a net profit of Rs 4 bn (up 501.9% YoY). Sales on the other hand came in at Rs 13 bn (up 36.4% YoY). Read on for a complete analysis of BIOCON LTD's quarterly results.

More Views on News

Most Popular

Use My Secret to Increase Your Trading Profits Today

Dec 10, 2019

What to do after every trade.

How We Made 14.64% Trading Profit in Just 2 Days

Dec 12, 2019

A high probability trade that worked to perfection for my subscribers.

Blue Chips Are Passe. Get into these Stocks for Outstanding Gains in 2020(Profit Hunter)

Dec 5, 2019

This corner of the market could provide more returns than blue chips in 2020.

Make the Most of the Smallcap Rebound with These Stocks(Profit Hunter)

Dec 3, 2019

Even amid a gloomy economic scenario, there are smallcaps that have grown earnings over last one and a half year and I believe these could be the strongest candidates for a smallcap rebound.

Stocks that Can Outperform No Matter what the RBI Does Today(The 5 Minute Wrapup)

Dec 5, 2019

I won't be surprised if these stocks repeat their 2002-2006 performance.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

FULFORD INDIA SHARE PRICE


Jul 30, 2015 (Close)

TRACK FULFORD INDIA

  • Track your investment in FULFORD INDIA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

FULFORD INDIA - ABBOTT INDIA COMPARISON

COMPARE FULFORD INDIA WITH

MARKET STATS